United Kingdom Daily Briefing

The Financial Times reported fresh US military strikes on Iranian rocket launchers, marking the first such action in weeks. For UK markets, the transmission is primarily through the oil price: Shell and BP constitute over 10% of the FTSE 100, and any sustained Iran risk premium in Brent crude ($108+ scenario) would directly lift the UK index's energy heavy-weights. The GBP/USD move will be the secondary tell — sterling has been correlated with the risk-on/off cycle, and a Middle East escalation typically pressures EM currencies and supports USD, creating a GBP headwind. Eva's read: Shell and BP are natural hedges against Iran-escalation scenarios; monitor Monday's Brent open.

The FT reports Big Tech companies received a $160 billion P&L boost from gains on their stakes in AI companies — a reminder that the AI equity appreciation wave is disproportionately concentrated in US mega-caps, not the FTSE 100. UK-listed technology names, concentrated on the AIM tier and secondary indices, have missed the AI equity gain cycle almost entirely. The FTSE's heavy weighting toward energy, mining, pharma and financials means UK investors are structurally underexposed to AI capex beneficiaries. Eva's assessment: the dividend yield gap (FTSE 100 ~4% vs US growth) is the UK's structural advantage, but the missing AI premium is the persistent discount. Expect continued capital drain to US tech vehicles from UK institutional allocators.

GSK rose 1.09% to $50.82 while AstraZeneca fell 1.11% in the same session — a classic within-sector rotation rather than a broad pharma direction. GSK's move aligns with its more defensive profile and lower-multiple valuation versus AZN's premium oncology pipeline positioning. As markets rotate toward lower-beta defensives ahead of September seasonal weakness, the GSK-over-AZN pair trade is a technically consistent expression. UK dividend investors tracking the GSK yield story (historically stable payout) should note the inflow pattern. The mining sector's 1.3% fall on gold price correction highlights that the commodity tailwind is reversing — defensives like GSK and UL are absorbing some of that flow.